Content
Designed by doctors, shaped by you
Side-by-side medication summaries to compare pros and cons, side effects, interactions, and more.
Content
The information provided here is NOT MEDICAL ADVICE and is for informational and educational purposes only. The drug comparison tool does not determine eligibility for medications or treatments provided via the Hims/Hers platform. Consultation with a healthcare provider is required to assess suitability for any medical treatment based on individual health and medical history. All product names and associated trademarks are the property of their respective owners.
Ozempic
Saxenda
Ozempic® (semaglutide) is an injectable medication used to improve blood sugar control in adults with type 2 diabetes and to reduce the risk of major cardiovascular events in individuals with established heart disease. It works by mimicking the hormone glucagon-like peptide-1 (GLP-1), which increases insulin secretion, decreases glucagon release, and slows gastric emptying. Administered once weekly, Ozempic is often part of a comprehensive treatment plan that includes diet and exercise. Common side effects include nausea, vomiting, diarrhea, and abdominal pain, and it should be used with caution in patients with a history of pancreatitis.
Saxenda® (liraglutide) is an injectable medication used for chronic weight management in adults with obesity or overweight with at least one weight-related condition, such as hypertension, type 2 diabetes, or high cholesterol. It works by mimicking the hormone glucagon-like peptide-1 (GLP-1), which helps regulate appetite and food intake, leading to reduced caloric consumption and weight loss. Administered once daily, Saxenda is used in conjunction with a reduced-calorie diet and increased physical activity. Common side effects include nausea, diarrhea, and constipation, and it should be used with caution in patients with a history of pancreatitis.
Prescription
Prescription
Glucagon-like peptide-1 (GLP-1) receptor agonist
Glucagon-like peptide-1 (GLP-1) receptor agonist
Ozempic (semaglutide) is indicated:
As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus
To reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus and established cardiovascular disease
Saxenda (liraglutide) is indicated:
As an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in:
Adult patients with an initial body mass index (BMI) of:
30 kg/m2 or greater (obese), or
27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, type 2 diabetes mellitus, or dyslipidemia)
Pediatric patients aged 12 years and older with:
Body weight above 60 kg and
An initial BMI corresponding to 30 kg/m2 for adults (obese) by international cut-offs
Typically taken as an injection once weekly
Comes in single-patient-use pens that deliver 0.25 mg, 0.5 mg, 1 mg, or 2 mg per injection
Typically taken as an injection once daily
Comes in single-patient-use pens that deliver 0.6 mg, 1.2 mg, 1.8 mg, 2.4 mg, or 3 mg per injection
The most common adverse reactions, reported in ≥5% of patients are:
Nausea
Vomiting
Diarrhea
Abdominal pain
Constipation
Most common adverse reactions, reported in greater than or equal to 5% are:
Nausea
Diarrhea
Constipation
Vomiting
Injection site reactions
Headache
Low blood sugar
Indigestion
Fatigue
Dizziness
Abdominal pain
Increased lipase
Upper abdominal pain
Fever
Inflammation of the digestive system
Personal or family history of medullary thyroid carcinoma or in patients with multiple endocrine neoplasia syndrome type 2
Serious hypersensitivity reaction to semaglutide or any of the excipients in Ozempic
Drug interactions: Ozempic delays gastric emptying and may impact the absorption of concomitantly administered oral medications
Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2
Hypersensitivity to liraglutide or any excipients in Saxenda
Pregnancy
Drug interactions: Saxenda delays gastric emptying. May impact absorption of concomitantly administered oral medications
Pancreatitis
Diabetic retinopathy complications
Never share an Ozempic pen between patients, even if the needle is changed
Low blood sugar: Concomitant use with an insulin secretagogue or insulin may increase the risk of low blood sugar, including severe low blood sugar
Acute kidney injury
Hypersensitivity reactions
Acute gallbladder disease
Females and males of reproductive potential: Discontinue Ozempic in women at least 2 months before a planned pregnancy due to the long washout period for semaglutide
Thyroid C-cell tumors
Acute pancreatitis
Acute gallbladder disease
Low blood sugar: Can occur in adults when Saxenda is used with an insulin secretagogue (e.g., a sulfonylurea) or insulin
Heart rate increase
Renal impairment
Hypersensitivity reactions
Suicidal behavior and ideation
WARNING: RISK OF THYROID C-CELL TUMORS
In rodents, semaglutide causes thyroid C-cell tumors. It is unknown whether Ozempic causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as the human relevance of semaglutide-induced rodent thyroid C-cell tumors has not been determined.
Ozempic is contraindicated in patients with a personal or family history of MTC or in patients with multiple endocrine neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk of MTC and symptoms of thyroid tumors.
WARNING: RISK OF THYROID C-CELL TUMORS
Liraglutide causes thyroid C-cell tumors at clinically relevant exposures in both genders of rats and mice. It is unknown whether Saxenda causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans, as the human relevance of liraglutide-induced rodent thyroid C-cell tumors has not been determined.
Saxenda is contraindicated in patients with a personal or family history of MTC or in patients with multiple endocrine neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk of MTC and the symptoms of thyroid tumors.
*This information is from the label for brand name Ozempic®. See the Full Prescribing Information for more complete information. Semaglutide, the active ingredient in Ozempic, is also the active ingredient in other brand-name medications, including Rybelsus® and Wegovy®, and this information may not be accurate for all medications that include the active ingredient semaglutide.
*This information is from the label for brand name Saxenda®. See the Full Prescribing Information for more complete information. Liraglutide, the active ingredient in Saxenda, is also the active ingredient in other brand-name medications, including Victoza®, and this information may not be accurate for all medications that include the active ingredient liraglutide.